On March 16, 2022, the Swedish Medical Technologies Product (MTP) Council released recommendations for SpaceOAR Hydrogel and Barrigel used to reduce the side effects of radiotherapy in prostate cancer. MTP Council recommended the regions wait with the use of technologies until more knowledge is available or use them only within the clinical trials.

In mid-March 2022, the Danish Health Data Agency (Sundhedsstyrelsen) published an update of the Health Care Classification System (Sundheds-væsenets Klassifikations System, SKS). The most significant changes include: ten new diagnosis codes, two procedure codes, and 143 additional codes (Tillægskoder) were added. The newly added procedure codes concern gastrointestinal and peripheral vascular procedures.

In February 2022, the National Institute for Health Research (NIHR) in England released six MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned biomarkers for assessing acute kidney injury, non-invasive testing for neovascular macular degeneration, decision support tool to prevent falls in older people, endometrial scratch, distal radius fracture, and test for group B Streptococcus. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

On March 18, 2022, the National Agency for Regional Health Services (AGENAS) announced the start of the time period for the submissions of proposals for setting up the National Telemonitoring Platform. The Platform shall bridge the gap between territorial disparities and offer greater integration between regional health services and national platforms through innovative solutions.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in March 2022. More than 15 recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, and neurovascular devices, as well as medical aids.

On March 23, 2022, the Norwegian Directorate of e-Health released an updated version of the National Laboratory code (NLK) system (Norsk laboratoriekodeverk 7280.62) to be implemented no later than May 01, 2022. Thirty-two codes were added, 91 codes have been changed, and one code has been terminated. NLK system has been used for activity-based reimbursement by the Norwegian Health Economics Administration (Helfo) in outpatient settings since 2018.

On March 3, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for new forms of care. A total of seven prioritized topics are defined. The preparation of a complete application can be supported for a period of up to six months with a grant of up to a maximum of €75,000. The deadline for submitting ideas is May 17, 2022, at noon.

On March 24, 2022, the entity developing the new outpatient lump-sum reimbursement system (Solutions Tarifaires Suisses AG, STS) announced that they are currently working on updating the system, which will be open for consultation again at the end of 2022 and then submitted to the Federal Council for final approval. The introduction of the new reimbursement system is expected in 2024.

On March 31, 2022, NHS England and NHS Improvement (NHSE/I) released the 2022/23 National Tariff Payment System (NTPS) to come into force on April 01, 2022. The aligned payment and incentive (API) model remains the central part of the 2022/23 NTPS, covering all secondary healthcare services, with few exceptions (e.g., diagnostic imaging, the contract value is lower than £30 million). National DRG (HRG) tariffs only remain for diagnostic imaging; other tariffs are published for benchmark purposes. Four new device categories were included, and two existing categories were updated to cover more devices in the 2022/23 High Cost Device List; In 2022/23, all High Cost devices are excluded from the fixed element and funded on a cost and volume basis.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in February 2022. More than 25 recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration of devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, neurovascular, and neuromodulation devices, as well as breast implants and medical aids. Except for this, CNEDiMTS published two negative opinions concerning transitional coverage of devices.

On March 18, 2022, the Norwegian National Institute of Public Health released an HTA report on the evaluation of surgical procedures for obesity treatment. The authors concluded that it is uncertain whether there is any difference in the risk of early mortality and the effect on weight status between different types of surgical procedures for the treatment of obesity.

In February 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (stereotactic radiosurgery for trigeminal neuralgia, and microwave ablation for primary or metastatic cancer in the lung), two new Diagnostic Guidance (EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules, PredictSURE IBD and IBDX to guide treatment of Crohn's disease), and four new Medtech Innovation Briefings (Insides System for managing intestinal failure, d-Nav insulin management app for type 2 diabetes, GaitSmart for personalized exercise rehabilitation, AposHealth for knee osteoarthritis)